Literature DB >> 18359762

The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates.

Wayne A Fritz1, Tien-Min Lin, Richard E Peterson.   

Abstract

Hypoxia-inducible factor-1 alpha (HIF-1alpha) and aryl hydrocarbon receptor nuclear translocator (ARNT) are basic helix-loop-helix/per-arnt-sim (PAS) family transcription factors. During angiogenesis and tumor growth, HIF-1alpha dimerizes with ARNT, inducing expression of many genes, including vascular endothelial growth factor (VEGF). ARNT also dimerizes with the aryl hydrocarbon receptor (AhR). AhR-null (Ahr(-/-)) transgenic adenocarcinoma of the mouse prostate (TRAMP) mice develop prostate tumors with greater frequency than AhR wild-type (Ahr(+/+)) TRAMP mice, even though prevalence of prostate epithelial hyperplasia is not inhibited. This suggests that Ahr inhibits prostate carcinogenesis. In TRAMP mice, prostatic epithelial hyperplasia results in stabilized HIF-1alpha, inducing expression of VEGF, a prerequisite for tumor growth and angiogenesis. Since ARNT is a common dimerization partner of AhR and HIF-1alpha, we hypothesized that the AhR inhibits prostate tumor formation by competing with HIF-1alpha for ARNT, thereby limiting VEGF production. Prostates from Ahr(+/+), Ahr(+/-) and Ahr(-/-) C57BL/6J TRAMP mice were cultured in the presence of graded concentrations of vanadate, an inducer of VEGF through the HIF-1alpha-ARNT pathway. Vanadate induced VEGF protein in a dose-dependent fashion in Ahr(+/-) and Ahr(-/-) TRAMP cultures, but not in Ahr(+/+) cultures. However, vanadate induced upstream proteins in the phosphatidylinositol 3-kinase-signaling cascade to a similar extent in TRAMPs of each Ahr genotype, evidenced by v-akt murine thymoma viral oncogene homolog (Akt) phosphorylation. These findings suggest that AhR sequesters ARNT, decreasing interaction with HIF-1alpha reducing VEGF production. Since VEGF is required for tumor vascularization and growth, these studies further suggest that reduction in VEGF correlates with inhibited prostate carcinogenesis in Ahr(+/+) TRAMP mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18359762      PMCID: PMC2902385          DOI: 10.1093/carcin/bgn069

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  52 in total

1.  A ligand for the aryl hydrocarbon receptor isolated from lung.

Authors:  Jiasheng Song; Margaret Clagett-Dame; Richard E Peterson; Mark E Hahn; William M Westler; Rafal R Sicinski; Hector F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-30       Impact factor: 11.205

2.  Aryl hydrocarbon receptor null mice develop cardiac hypertrophy and increased hypoxia-inducible factor-1alpha in the absence of cardiac hypoxia.

Authors:  E A Thackaberry; D M Gabaldon; M K Walker; S M Smith
Journal:  Cardiovasc Toxicol       Date:  2002       Impact factor: 3.231

Review 3.  The development of androgen-independent prostate cancer.

Authors:  B J Feldman; D Feldman
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

Review 4.  Pathological and molecular aspects of prostate cancer.

Authors:  Angelo M DeMarzo; William G Nelson; William B Isaacs; Jonathan I Epstein
Journal:  Lancet       Date:  2003-03-15       Impact factor: 79.321

5.  Vascular endothelial growth factor rescues 2,3,7,8-tetrachlorodibenzo-p-dioxin inhibition of coronary vasculogenesis.

Authors:  Irena D Ivnitski-Steele; Mary K Walker
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2003-07

6.  Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model.

Authors:  Paula J Kaplan-Lefko; Tsuey-Ming Chen; Michael M Ittmann; Roberto J Barrios; Gustavo E Ayala; Wendy J Huss; Lisette A Maddison; Barbara A Foster; Norman M Greenberg
Journal:  Prostate       Date:  2003-05-15       Impact factor: 4.104

Review 7.  PI3K/Akt signalling pathway and cancer.

Authors:  Juan Angel Fresno Vara; Enrique Casado; Javier de Castro; Paloma Cejas; Cristóbal Belda-Iniesta; Manuel González-Barón
Journal:  Cancer Treat Rev       Date:  2004-04       Impact factor: 12.111

8.  Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation.

Authors:  Derek Morrow; Chunhua Qin; Roger Smith; Stephen Safe
Journal:  J Steroid Biochem Mol Biol       Date:  2004-01       Impact factor: 4.292

Review 9.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

10.  Effects of aryl hydrocarbon receptor null mutation and in utero and lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure on prostate and seminal vesicle development in C57BL/6 mice.

Authors:  Tien-Min Lin; Kinarm Ko; Robert W Moore; Ulla Simanainen; Terry D Oberley; Richard E Peterson
Journal:  Toxicol Sci       Date:  2002-08       Impact factor: 4.849

View more
  20 in total

Review 1.  Role of xenobiotic metabolism in cancer: involvement of transcriptional and miRNA regulation of P450s.

Authors:  Viola Tamási; Katalin Monostory; Russell A Prough; András Falus
Journal:  Cell Mol Life Sci       Date:  2010-12-24       Impact factor: 9.261

Review 2.  Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia.

Authors:  Vatsal Mehta; Chad M Vezina
Journal:  Differentiation       Date:  2011 Nov-Dec       Impact factor: 3.880

3.  Aryl hydrocarbon receptor agonists upregulate VEGF secretion from bronchial epithelial cells.

Authors:  Ming-Ju Tsai; Tsu-Nai Wang; Yi-Shiuan Lin; Po-Lin Kuo; Ya-Ling Hsu; Ming-Shyan Huang
Journal:  J Mol Med (Berl)       Date:  2015-06-17       Impact factor: 4.599

Review 4.  Vascular endothelial growth factor receptor-2 in breast cancer.

Authors:  Shanchun Guo; Laronna S Colbert; Miles Fuller; Yuanyuan Zhang; Ruben R Gonzalez-Perez
Journal:  Biochim Biophys Acta       Date:  2010-05-11

Review 5.  The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities.

Authors:  Jianfei Qi; Maurizio Pellecchia; Ze'ev A Ronai
Journal:  Oncotarget       Date:  2010-09

Review 6.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

7.  Auto-induction mechanism of aryl hydrocarbon receptor 2 (AHR2) gene by TCDD-activated AHR1 and AHR2 in the red seabream (Pagrus major).

Authors:  Su-Min Bak; Midori Iida; Anatoly A Soshilov; Michael S Denison; Hisato Iwata; Eun-Young Kim
Journal:  Arch Toxicol       Date:  2016-05-17       Impact factor: 5.153

8.  Aryl hydrocarbon receptor is activated by glucose and regulates the thrombospondin-1 gene promoter in endothelial cells.

Authors:  Pankaj Dabir; Tina E Marinic; Irene Krukovets; Olga I Stenina
Journal:  Circ Res       Date:  2008-05-30       Impact factor: 17.367

Review 9.  bHLH-PAS proteins in cancer.

Authors:  David C Bersten; Adrienne E Sullivan; Daniel J Peet; Murray L Whitelaw
Journal:  Nat Rev Cancer       Date:  2013-12       Impact factor: 60.716

Review 10.  AHR signaling in prostate growth, morphogenesis, and disease.

Authors:  Chad M Vezina; Tien-Min Lin; Richard E Peterson
Journal:  Biochem Pharmacol       Date:  2008-10-14       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.